Literature DB >> 27282099

Higher visceral to subcutaneous fat ratio is associated with small intestinal bacterial overgrowth.

A Fialho2, A Fialho2, P Thota3, A McCullough3, B Shen3.   

Abstract

BACKGROUND AND AIMS: There is a lack of studies evaluating the association between small intestinal bacterial overgrowth (SIBO) and abdominal fat. The aim of this study was to evaluate whether visceral fat area (VFA), subcutaneous fat area (SFA) or visceral to subcutaneous fat ratio (VFA/SFA ratio) were associated with SIBO. METHODS AND
RESULTS: In this case-control study, 152 eligible patients submitted to glucose hydrogen/methane breath test who also had computed tomography (CT) of the abdomen performed were included. Clinical and demographic information was obtained. VFA and SFA were measured using Image J software at lumbar 3 level on CT cross-sectional image of the 152 patients included in this study, 68 patients (44.7%) tested positive for SIBO. In the univariate analysis, the presence of SIBO was associated with older age (65.2 ± 1.5 vs. 59.3 ± 1.5, p = 0.007); type 2 diabetes mellitus (33.8% vs. 17.9%; p = 0.019); hypertension (63.2% vs. 39.3%; p = 0.003); metabolic syndrome (85.3% vs. 64.3%; p = 0.003); and higher VFA/SFA ratio (1.0 ± 0.1 vs. 0.7 ± 0.1; p < 0.001). In multivariate analysis, metabolic syndrome (odds ratio [OR]: 2.5; 95% confidence interval [CI]: 1.1-5.7; p = 0.035) and higher VFA/SFA ratio (OR: 3.3; 95% CI: 1.6-7.2; p = 0.002) remained independently associated with SIBO.
CONCLUSION: The presence of SIBO was found to be associated with high VFA/SFA ratio measured from cross-sectional CT image.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Obesity; Small intestine bacterial overgrowth; Visceral fat

Mesh:

Year:  2016        PMID: 27282099     DOI: 10.1016/j.numecd.2016.04.007

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

1.  Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association.

Authors:  Uday C Ghoshal; Sanjeev Sachdeva; Ujjala Ghoshal; Asha Misra; Amarender Singh Puri; Nitesh Pratap; Ayesha Shah; M Masudur Rahman; Kok Ann Gwee; Victoria P Y Tan; Tahmeed Ahmed; Yeong Yeh Lee; B S Ramakrishna; Rupjyoti Talukdar; S V Rana; Saroj K Sinha; Minhu Chen; Nayoung Kim; Gerald Holtmann
Journal:  Indian J Gastroenterol       Date:  2022-10-10

Review 2.  The relationship between vitamin C status, the gut-liver axis, and metabolic syndrome.

Authors:  Maret G Traber; Garry R Buettner; Richard S Bruno
Journal:  Redox Biol       Date:  2018-12-26       Impact factor: 11.799

3.  Intestinal-level anti-inflammatory bioactivities of catechin-rich green tea: Rationale, design, and methods of a double-blind, randomized, placebo-controlled crossover trial in metabolic syndrome and healthy adults.

Authors:  Joanna K Hodges; Jiangjiang Zhu; Zhongtang Yu; Yael Vodovotz; Guy Brock; Geoffrey Y Sasaki; Priyankar Dey; Richard S Bruno
Journal:  Contemp Clin Trials Commun       Date:  2019-11-20

4.  Effect of eradicating hydrogen-forming small intestinal bacterial overgrowth with rifaximin on body weight change.

Authors:  Seok-Hoon Lee; Doo-Yeoun Cho; Nam-Seok Joo; Kyu-Nam Kim
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.